Research Article

Dual Inhibition of BMP and WNT Signals Promotes Pancreatic Differentiation from Human Pluripotent Stem Cells

Mengtian Tan,1,2 Lai Jiang,1 Yinglei Li,1 and Wei Jiang1,3

1Department of Biological Repositories, Zhongnan Hospital & Medical Research Institute, Wuhan University, Wuhan 430071, China
2Affiliated Hospital of Hebei University of Engineering, Handan 056038, China
3Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, China

Correspondence should be addressed to Wei Jiang; jiangw.mri@whu.edu.cn

Received 26 July 2019; Revised 1 October 2019; Accepted 4 November 2019; Published 1 December 2019

Academic Editor: Heinrich Sauer

Copyright © 2019 Mengtian Tan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pathological or functional loss of pancreatic beta cells is the cause of diabetes. Understanding how signaling pathways regulate pancreatic lineage and searching for combinations of signal modulators to promote pancreatic differentiation will definitely facilitate the robust generation of functional beta cells for curing hyperglycemia. In this study, we first tested the effect of several potent BMP inhibitors on pancreatic differentiation using human embryonic stem cells. Next, we examined the endodermal lineage bias upon potent BMP inhibitor treatment and further checked the crosstalk between signal pathways governing endodermal lineage determination. Furthermore, we improved current pancreatic differentiation system based on the signaling pathway study. Finally, we used human-induced pluripotent stem cells to validate our finding. We found BMP inhibitors indeed not only blocked hepatic lineage but also impeded intestinal lineage from human definitive endoderm unexpectedly. Signaling pathway analysis indicated potent BMP inhibitor resulted in the decrease of WNT signal activity and inhibition of WNT could contribute to the improved pancreatic differentiation. Herein, we combined the dual inhibition of BMP and WNT signaling and greatly enhanced human pancreatic progenitor differentiation as well as beta cell generation from both embryonic stem cells and induced pluripotent stem cells. Conclusively, our present work identified the crosstalk between the BMP and WNT signal pathways during human endoderm patterning and pancreas specification, and provided an improved in vitro pancreatic directed differentiation protocol from human pluripotent stem cells.

1. Introduction

Diabetes mellitus is characterized by chronic hyperglycemia due to the loss of either beta cell mass or beta cell function and could lead to severe metabolic syndrome. There are around 425 million diabetes patients in the world, and the number is increasing according to the International Diabetes Federation (IDF) 2017 report. Traditional methods of treating diabetes include burdensome daily insulin-sensitizing drugs or insulin injection, which can only alleviate symptoms of hyperglycemia, but cannot maintain normoglycemia continually and thus fail to fundamentally cure diabetes. Islet transplantation provides an effective and reliable strategy to replace the damaged cells, but is largely limited by the shortage of cadaveric islet source [1].

Human pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), could form multiple cell types and tissues composing of our body [2, 3]. Therefore, production of functional beta cells from human ESCs or iPSCs could be a promising choice for the cell replacement therapy of diabetes. A lot of efforts have been put in the last decades to direct human pluripotent stem cells to differentiate into functional beta cells in vitro and remarkable progresses have been recently achieved [4–9]. In order to generate robust beta cells from ESCs which represent the embryonic epiblast stage, pancreatic specification from differentiated definitive endoderm is a key point for the subsequent step [10]. The Nodal signaling pathway has been revealed as the main regulator of endoderm generation, but further endoderm patterning is more complicated...
and lacks of detailed studies in terms of signal combinations regulating individual endodermal lineage [11]. Retinoic acid (RA) is a well-known pathway to be utilized to direct pancreas specification, which also facilitates liver progenitor development [5, 12]. Bone morphogenetic protein (BMP) is required for hepatic specification from definitive endoderm both in human and mouse [13, 14]. NOGGIN, an inhibitory protein of BMP signaling, is thus utilized in pancreatic differentiation together with RA [4, 5, 8]. In addition, more potent compounds targeting the same pathway have been reported, such as retinoid analog TTNPB to replace the endogenous version all-trans RA [15] and LDN for NOGGIN [6, 7].

Previously, we have established a chemically defined protocol to direct human ESCs and iPSCs to differentiate into pancreatic lineage [5, 9, 16], and performed RNA sequencing analysis which pointed out BMP signaling as a downregulated pathway during pancreatic lineage specification from human ESC-derived definitive endoderm [17]. Therefore, here we tested several more stable and powerful chemical compounds targeting the BMP pathway to further promote pancreatic differentiation efficiency, and identified LDN193189 and K02288 indeed improving PDX1-positive pancreatic progenitor differentiation while surprisingly decreased CDX2-positive population. Since CDX2-positive cells represent intestine/colon lineages which are usually driven by the WNT signaling pathway, we had examined the crossstalk between the BMP and WNT signal pathways. Our data suggested that BMP inhibitors led to lower WNT activity and suppressed WNT signaling facilitated pancreatic lineage differentiation. Finally, we combined the dual treatment and observed the dual inhibition of BMP and WNT largely promoted pancreatic progenitor differentiation and beta cell generation.

2. Materials and Methods

2.1. Cell Culture and Differentiation. Human ESC line HUES8 [17] and iPSC line PGP1 [18] were cultured on Matrigel (BD Biosciences)-coated tissue culture plates with mTeSR1 medium accordingly (STEMCELL Technologies). For regular passaging, cells were split around 1:10 every 4-5 days with accutase for HUES8 or versene (Invitrogen) for PGP1, respectively.

For endodermal and pancreatic differentiation, we utilized previous protocols [5, 6, 16] with some modifications. First, human ESCs or iPSCs were seeded at the density of 30,000 to 50,000 cells per well for 24-well plate precoated with Matrigel. For induction of definitive endoderm, cells were treated with 100 ng/mL Activin A and 50 ng/mL Wnt3a recombinant protein for 1-2 days in 1:1 IMDM (Gibco) and F12 (Gibco) medium supplemented with 1% BSA, 1× B27 without vitamin A, and 1% penicillin-streptomycin (Invitrogen) and then followed by another 2 days with Wnt3a withdrawing. Then, differentiated definitive endoderm cells were cultured in MCDB131 (Sigma) for pancreatic progenitor differentiation, supplemented with 1.5 g/L sodium bicarbonate, 10 mM glucose (Invitrogen), 0.5% BSA, 0.25 mM ascorbic acid, 1× ITS-X, 1× GlutaMAX, and 1% penicillin-streptomycin. In addition, 50 ng/mL KGF, 0.5 μM SANT1, 100 nM TTNPB, and 500 nM PDBU were added to this basal medium for 8 days, and with different individual BMP inhibitors (2 μM K02288, 200 nM LDN193189, 2 μM LDN214117, 2 μM Dorosomorphin, 100 ng/mL Noggin, and individual WNT inhibitor (2 μM XAV-939 or 2 μM IWR-1). For following beta cell differentiation, differentiated pancreatic progenitor cells were cultured in MCDB131 with 20 mM glucose and 2% BSA, 1.5 g/L sodium bicarbonate, 0.05 mM ascorbic acid, 1× ITS-X, 1× GlutaMAX, and 1% penicillin-streptomycin. In addition, 200 nM LDN193189, 1 μM T3, 10 μM Repsox, 10 μM YO-01027, and 10 μM zinc sulfate were added for the first 5 days. In the last 5 days, cells were cultured in MCDB131 with 20 mM glucose and 2% BSA, 1.5 g/L sodium bicarbonate, 1× GlutaMAX, 1% penicillin-streptomycin, and 0.05 mM ascorbic acid. In addition, 1 μM T3, 10 μM Repsox, 10 μM Trolox, 10 μg/mL heparin sodium, 2 μM R428, 10 μM zinc sulfate, and 10 mM N-cys were added. All the chemical compounds are commercially available and the detailed information is listed in Table S1.

2.2. Western Blotting Analysis. Cells were harvested and lysed on ice with RIPA buffer supplemented with cOmplete Tablets EDTA-free EASYpack (Roche). Proteins (20 μg) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane (Millipore). The membrane was blocked with 5% skim milk in TBS buffer with 0.1% Tween-20 and incubated with antibodies against beta-catenin, active beta-catenin, goat anti-human PDX1, or GAPDH overnight at 4°C. Then, the membrane was washed and incubated with secondary antibodies at room temperature for 2 hours. After washing, the membrane was visualized with SuperSignal® West Pico Chemiluminescent Substrate (Thermo Fisher).

2.3. Immunofluorescence Staining. Cells were washed with PBS and fixed in 4% PFA for 20 minutes at room temperature. After washed with PBS for three times, the cells were blocked and permeabilized with PBS containing 10% normal donkey serum and 0.1% Triton X-100 for 2 hours at room temperature. Then, diluted primary antibodies were added and incubated overnight at 4°C. The primary antibodies used included goat anti-human PDX1, rabbit anti-human PDX1, rabbit anti-human AFP, rabbit anti-human CDX2, mouse anti-human CHGA (Chromogranin A), rabbit anti-human CHGA, rabbit anti-human GLUCAGON, mouse anti-human INSULIN, rabbit anti-human INSULIN, rat anti-C-Peptide, mouse anti-NKX6-1, mouse anti-pY489-beta-catenine, rabbit anti-beta-catenin, mouse anti-Pro-INSULIN, and goat anti-human SOX2. After washing with PBS for five times, the cells were incubated with diluted TRITC- or 488-conjugated donkey anti-rabbit, goat, mouse anti-Pro-INSULIN, and 4,6-diamidino-2-phenylindole (DAPI, Sigma, Cat #102362/76001). The detailed information of all the used antibodies is listed in Table S2.

2.4. Flow Cytometry. Cells were dissociated with 0.05% trypsin-EDTA solution and incubated at 37°C for 5-10
minutes. Cells were suspended in 1 mL FACS Wash Buffer and collected by centrifuging at 1000 rpm for 5 minutes. Then, the cells were suspended in commercially available fixation/permeabilization solution (RR&D) for 45 minutes at 4°C and then washed with Perm/Wash solution. Primary antibodies PDX1, CDX2, and AFP or isotype control IgG were incubated with suspended single cells in 200 μL Perm/Wash overnight at 4°C. After wash, secondary antibodies were incubated at room temperature for 2 hours in dark. Then, samples were transferred in a total volume of 300-500 μL FACS Buffer and analyzed with the flow cytometer (FACS Celsesta).

2.5. RNA Isolation and Quantitative RT-PCR. RNA was extracted using Hipure Total RNA Mini kit (Magen), and cDNA was generated immediately following RNA isolation using All-in-One cDNA Synthesis SuperMix (Bimake) according to the manufacturer’s manual. The sequences of quantitative PCR primers are listed as below: PDX1 (TTAGGATGTGGCAAATTTCTTTGTT, GGCACCTGTGCTTG TCTTCA); INSULIN (CGACGCTTTTGGAACCAACAC, CCCGCACACTAAGGTAGAGA); NGN3 (CTAAGACGGATGGCAGCTGA, GAGGTTGTCATTCGATTGCC); NEROUD (ACCAAATCGTACAGGGAGT, CTCGTCTGAGAACCTGAGACA); AXIN2 (CTGCTCCACGAATACTGACA, AGTGTTGAGGATCACCAC GAAAC); WNT3 (AGTTGCTTGGGAGCAGGAG, CTCGCTGCTACCAATTTC); CDX2 (CTGGAGCTTGGAGAA); and DIF (Bio-Rad) using 2X SYBR Green qPCR kit (Bimake).

2.6. Glucose-Stimulated INSULIN/C-Peptide Secretion. Differentiated beta cells at the final stage were washed with Krebs buffer containing 2 mM glucose for more than 2 hours to remove the residual INSULIN. After washing three times with Krebs buffer, cells were incubated with low glucose (2 mM) in Krebs buffer for 30 minutes, and supernatant was collected; then, cells were further washed three times in Krebs buffer and incubated with high glucose (20 mM) or 30 mM KCl in Krebs buffer for another 30 minutes, and then, supernatant was collected. All the supernatant samples were processed to analyze the concentration of INSULIN by Ultrasensitive Insulin ELISA (Mercodia) and C-Peptide by Ultrasensitive C-Peptide ELISA (Mercodia). For normalization, protein content of the cell lysate was determined using the BCA kit (Thermo Fisher).

2.7. Statistical Analysis. All experiments were performed at least three times. The data are presented as the mean ± SD. All statistical analyses were performed using SPSS 22.0 software. Student's t-test was conducted between two groups. Statistical significance was set at p values < 0.05.

3. Results

3.1. Compound Test for BMP Inhibitors to Improve the Generation of PDX1-Positive Cells. Our previous study profiled the transcriptome dynamics of entire pancreatic lineage including undifferentiated ESCs, purified definitive endoderm, and pancreatic progenitors, as well as alpha and beta cells from primary human islets [17]. By focusing on the pancreatic lineage specification stage (i.e., from definitive endoderm to pancreatic progenitor), we found the BMP signaling pathway significantly enriched [17]. NOGGIN, as a well-recognized BMP antagonist, has been broadly used in previous protocols [4, 5, 8] and effectively directed pancreatic differentiation. However, considering the cost and efficiency, we performed a small test for chemical compounds inhibiting the BMP and TGFbeta signaling pathway, including LDN193189 (Selleck, S2618) targeting ALK2/3 which was already used in a previous report [6], K02288 (Selleck, S7359) blocking ALK1/2/3/6, LDN214117 (Selleck, S7627) exclusively targeting ALK2, and Dorsomorphin (Compound C, Selleck, S7840) recognized as BMP inhibitor and AMPK inhibitor. NOGGIN (Peprotech, 120-10C) and no BMP inhibitor were served as control.

We used human ESC line HUES8 with an integrated protocol based on our previous study [16, 17] and recent report [6]. After generating definitive endoderm, we treated with different compound inhibitors in the same condition (Figure 1(a)), and evaluated the pancreatic differentiation effect. PDX1 is one of the most important transcription factors to specify pancreatic fate and beta cell maturation [19]; herein, we examined the ratio of PDX1-positive cells at progenitor stage by immunofluorescence assay and later quantitatively confirmed by flow cytometric analysis. The immunostaining data indicated LDN193189 treatment induced the most PDX1-positive cells (Figure S1). The flow cytometric analysis revealed that K02288 and LDN193189 were vigorous candidates with around 25% PDX1-positive cells, compared to less than 10% for NOGGIN (Figure 1(b), S1). Consistently, we observed that hepatic marker AFP exhibited a significant decrease upon treated with various BMP inhibitors (Figure S1).

3.2. The Endodermal Lineage Patterning while Inhibiting BMP Signal. We further verified the effect of BMP inhibitor (BMPi for short) LDN193189 (Figure 1) and K02288 (Figure S2) on endodermal lineage specification from differentiated definitive endoderm. We observed that the percentage of PDX1-positive cells greatly increased after BMPi treatment by immunofluorescence (Figure 1(c), S2), which was further confirmed by flow cytometry analysis (Figure 1(d), S2). Since NKX6-1-expressing cells within PDX1-positive population indicated the bona fide pancreatic progenitors [4, 6, 7], we also checked NKX6-1, showing upregulated expression in the BMPi treatment group both in protein and mRNA levels (Figures 1(c), 1(e), and 1(f), S2).

Then, we investigated other nonpancreatic lineages in the differentiated endoderm derivatives after BMPi treatment. The pancreas is derived from embryonic gut tube, which also forms the lung, gastric fundus, liver, intestine, colon, and
Figure 1: Continued.
AMPK), and NOGGIN were added in each experimental group at PP stage (no BMP inhibitor) and BMPi (shown for LDN193189) in PP stage with pancreatic markers PDX1 and NKX6-1, and liver marker AFP, intestine marker CDX2, and gastric marker SOX2. Dorsmorphin (targeting BMP and PDX1-positive cells determined by intracellular fluorescence analysis (Figure 1(c), S2), as well as the RNA expression level (Figure 1(e), S2). There was no significant change of SOX2-positive cells possibly due to the generally lower expression level (Figure 1(c)). The PDX1 and NKX6-1 coexpressing cells appeared upon BMP inhibition (Figure 1(f), S2). Taken together, we observed increased pancreatic differentiation while decreased expected hepatic differentiation and unexpected intestinal differentiation after BMPi treatment.

3.3. BMP Inhibition Led to Suppressed WNT/Beta-Catenin Signaling Activity during Pancreatic Differentiation. To understand the result that BMPi promoted pancreatic differentiation and inhibited intestinal differentiation (Figure 1), we investigated whether inhibition of BMP signaling during pancreatic differentiation affected the WNT signaling pathway, which was considered as the major inducer of intestinal lineage [21]. First, we checked the expression levels of downstream genes to evaluate the activity of the WNT signaling pathway. The data showed all checked canonical WNT downstream genes, including WNT3, TWIST1, AXIN2, and MYC, and exhibited significant downregulation after inhibiting BMP (Figure 2(a), S3 for another BMP inhibitor K02288), indicating lower WNT signaling activity. Then, we checked the protein level and phosphorylation level of beta-catenin, the main effector of the WNT signaling pathway. Cytosolic beta-catenin phosphorylation/degradation is the essence of WNT signaling [22]. Phosphorylation of beta-catenin at serine 37 and serine 33 by GSK3 will lead to its ubiquitination and degradation [23], while hyperphosphorylation on tyrosine residues will make beta-catenin dissociate from N-cadherin and being on-state situation [24]. Thus, nonphosphorylated beta-catenin (Ser33/37/Thr41) or Y489-phosphorylated beta-catenin represents nuclear-bound activated form to determine WNT/beta-catenin activity. Therefore, we collected the cell lysate to examine protein expression and the results showed the BMPi treatment group exhibiting higher PDX1 protein level and lower active beta-catenin protein level albeit unchanged total beta-catenin level (Figure 2(b)). We further looked into the coexpression and subcellular localization of beta-catenin and active beta-catenin with PDX1, respectively (Figures 2(c) and 2(d), S3). The total beta-catenin protein showed no difference in the control or BMPi group in both PDX1-positive cells and PDX1-negative cells (Figure 2(c)), as beta-catenin is not only the downstream of WNT signal but also the cytoskeletal structure protein with Ca2+-dependent CAMs [24]. In contrast, nucleus-located activated beta-catenin signals indeed decreased in BMPi condition compared with control (Figure 2(d), S3). Furthermore, the PDX1-positive cells exhibited apparently much weaker staining of beta-catenin in the nucleus, suggesting lower activity of WNT signaling, while PDX1-negative cells had upregulated nucleus-located beta-catenin protein, suggesting higher activity of WNT signaling (Figure 2(d), S3). Taken together, these data suggested the inhibition of BMP led to lower activity of the WNT signal pathway.

**Figure 1:** The endodermal lineage differentiation while BMP inhibited. (a) The schematic diagram displayed differentiation protocol (ESC: embryonic stem cells; DE: definitive endoderm stage; PP: pancreatic progenitors; beta cell: pancreatic beta cell stage). (b) The statistics of PDX1-positive cells determined by intracellular flow cytometry with different BMP inhibitors. The control group had no inhibitor of BMP, LDN193189 (targeting ALK2/3), K02288 (targeting ALK1/2/3/6), LDN214117 (targeting ALK2), Dorsmorphin (targeting BMP and AMPK), and NOGGIN were added in each experimental group at PP stage (n = 3). (c) Immunofluorescence results exhibited the control group (no BMP inhibitor) and BMPi (shown for LDN193189) in PP stage with pancreatic markers PDX1 and NKX6-1, and liver marker AFP, intestine marker CDX2, and gastric marker SOX2. DAPI (blue) represented all cells for internal control. Scale bars for enlargement inset, 50 μm. SOX2 antibody had been validated previously. (d) Flow cytometry showed the analysis of different endodermal lineages (PDX1 for pancreatic lineage; AFP for hepatic lineage; CDX2 for intestinal lineage) (n = 3). (e) mRNA expression levels of PDX1, NKX6-1, AFP, and CDX2 in the control group and BMPi group. ** represented for p value < 0.01 and *** for p value < 0.001 by Student's t test (n = 3). (f) Costaining PDX1 and NKX6-1 represented bona fide pancreatic progenitors in BMPi condition.
3.4. Direct Inhibition of WNT Could Promote Pancreatic Differentiation and Beta Cell Generation. Since BMP inhibition improved pancreatic differentiation along with lower WNT/beta-catenin activity, we attempted to block WNT (labeled as WNTi) in pancreatic differentiation from definitive endoderm stage (Figure 1(a)). WNT inhibition alone by XAV939 or IWR-1 indeed showed improved effect in terms of promoting pancreatic lineage marker expression and decreasing liver and intestinal lineage marker expression (Figures 3(a) and 3(b)); however, dual inhibition exhibited much higher expression levels of pancreatic markers and more PDX1-positive cells (Figure 3(c)).
3.5. Dual Inhibition of BMP and WNT in Pancreatic Differentiation. Since dual inhibition of BMP and WNT showed the best induction effect of pancreatic differentiation (Figure 3(c)), we looked into the combination of dual inhibition of BMP and WNT signals. Very dramatically, double inhibition of BMP and WNT signals (labeled as "Dual i") largely increased the percentage of PDX1-positive cells up to about 50% (Figures 4(a)–4(c)). Meanwhile, we checked other endodermal lineages and found the mildly decreased AFP-positive hepatic lineage and dramatically lower CDX2-positive intestinal lineage (less than 10%) (Figures 4(a) and 4(b)). We also performed mRNA analysis and found "Dual i" indeed increased the PDX1 and NKX6-1 expression level and reduced AFP and CDX2 levels (Figure 4(c)). More importantly, PDX1- and NKX6-1-double positive cells also significantly increased in “Dual i” (Figure 4(d)), indicating that bona fide pancreatic progenitors were capable of generating beta cells [4, 6, 7]. Our data together showed that the pancreatic lineage differentiation was greatly enhanced by the “Dual i” treatment at the expense of hepatic and intestinal lineage.

We further checked whether the dual treatment of BMPi and WNTi could also give rise to better beta cell efficiency in the following beta cell differentiation condition. To evaluate the beta cell generation, we costained the functional marker INSULIN with transcription factors PDX1 and NKX6-1. Immunofluorescence data showed that dual inhibition resulted in the higher ratio of INSULIN-positive cells.

Figure 3: Inhibition of WNT could facilitate the generation of pancreatic progenitor cells. (a) Immunofluorescence results exhibited the control group (no BMP inhibitor) and WNTi (using WNT inhibitor XAV939) at PP stage with pancreatic marker PDX1, liver marker AFP, and intestine marker CDX2. DAPI (blue) represented all cells for internal control. Scale bars for enlargement inset, 50 μm. (b) Costaining PDX1 and NKX6-1 represented bona fide pancreatic progenitors in WNTi (using WNT inhibitor IWR-1) condition. (c) Flow cytometry showed the analysis of PDX1-positive cells.
Figure 4: Further inhibition of WNT and BMP could promote pancreatic progenitor differentiation. (a) The immunofluorescence showed the BMPi (BMP inhibitor only) and "Dual i" (BMP inhibitor LDN193189 plus WNT inhibitor XAV939 together) groups with endodermal lineage marker in pancreatic progenitor stage. The expression levels of PDX1 and NKX6-1 (pancreatic lineage) were much higher in "Dual i," while AFP (liver lineage) and CDX2 (intestine lineage) fell down in "Dual i." Scale bars for enlargement inset, 50 μm. (b) Flow cytometry showed the analysis of different endodermal lineage markers (PDX1, AFP, CDX2) between the BMPi and "Dual i" (n = 3). (c) mRNA expression of endodermal lineages (PDX1, NKX6-1, AFP, CDX2) analyzed in BMPi and "Dual i." * represented for p value < 0.05 and ** for p value < 0.01 by Student’s t-test (n = 3). (d) Costaining PDX1 and NKX6-1 represented bona fide pancreatic progenitors in "Dual i" and BMPi conditions.
costained with PDX1 or NKX6-1 (Figures 5(a) and 5(b)). Since Pro-INSULIN is the precursor for INSULIN maturation and thus represents the de novo production of INSULIN, we examined the expression of Pro-INSULIN. The results showed the “Dual i” group resulting in much higher positive cells for Pro-INSULIN with PDX1 (Figure 5(c)). We further surveyed the RNA expression level and indeed dual inhibition treatment exhibited higher expression levels of PDX1, NKX6-1, and INSULIN genes (Figure 5(d)).

3.6. Dual Inhibition of BMP and WNT in Pancreatic Differentiation from Human iPSCs. We chose another cell line human iPSC PGP1 to evaluate the common role of the signaling crosstalk between BMP and WNT during pancreatic specification. We first generated definitive endoderm cells and treated with BMP inhibitor LDN193189 along with pancreatic specification condition. Similarly, LDN193189 significantly increased PDX1-positive cells and greatly decreased CDX2-positive cells as expected (Figure 6(a)). Consistent with this observation, the protein level of active beta-catenin in the BMPi group was significantly lower than the control group while there was no change for the total beta-catenin level (Figure 6(b)). The expression levels of canonical WNT target genes including WNT3, TWIST1, AXIN2, and MYC were downregulated in the BMPi group (Figure 6(c)). These data indicated lower WNT activity appearing upon BMP inhibition, which was the same as that we observed in human ESCs (Figure 2).

We further utilized the combination of dual inhibition of BMP and WNT signaling for pancreatic differentiation and performed the flow cytometric analysis. The result showed “Dual i” indeed increased the PDX1-positive cells in progenitor stage (Figure 6(d)). Consistently, immunostaining result indicated dual inhibition of BMP and WNT generating much higher PDX1- and NKX6-1-double positive cells at progenitor stage (Figure 6(e)). We further evaluated the beta cell differentiation efficiency by RT-qPCR and immunostaining assays. Dual inhibition largely improved the mRNA expression levels of PDX1 and INSULIN (Figure 6(f)). Similarly, dual inhibition of BMP and WNT generated much higher PDX1- and INSULIN-double positive and PDX1-positive cells in iPSC (Figure 6(g)).

3.7. Functional Analysis of Differentiated Beta Cells by Dual Inhibition. Since dual inhibition of BMP and WNT resulted in higher PDX1- or NKX6-1- with INSULIN- or Pro-INSULIN-double positive cells, we next examined the beta cell identity. First, we performed more costaining to confirm PDX1 and NKX6-1 coexpressed with C-Peptide (Figure 7(a)). In addition, the expression of INSULIN/C-Peptide was exclusive, because INSULIN/C-Peptide-positive cells were not expressing GLUCAGON (Figure 7(b)), but indeed costained with secretory protein CHGA (Chromogranin A) (Figure 7(c)). By further quantitative flow cytometric analysis, approximately 21% of cells coexpressed INSULIN and PDX1 in differentiated beta cells, and 25% of cells were PDX1 and Pro-INSULIN-double positive cells (Figure 7(d)). The most important functional feature of beta cells is the capacity to secret INSULIN response to stimuli such as glucose and KCl. We challenged the differentiated beta cells with 20 mM glucose and we found the differentiated cells secreted INSULIN upon high glucose stimulation with around 2.5 ± 1.3-fold than basal glucose treatment. C-Peptide analysis also indicated the differentiated cells released more C-Peptide in high glucose (1.5 ± 0.8-fold) and KCl (1.6 ± 1.9-fold) conditions compared to basal glucose level (Figure 7(e)). Taken together, the differentiated beta cells through dual inhibition of BMP and WNT indeed exhibited the characteristic of functional beta cells.

4. Discussion

Our present study reported an unexpected but important result that BMP inhibition could repress WNT activity during pancreatic differentiation (Figures 1 and 2, S2 and S3) and dual inhibition treatment of BMP and WNT signals could greatly promote pancreatic differentiation from human ESCs (Figures 4 and 5) and iPSCs (Figure 6) as well. This finding not only facilitated the pancreatic beta cell generation for potential cell therapy and disease modeling but also highlighted the importance of crosstalk among signaling pathways in cell fate determination.

Endodermal organ patterning was a very complicated process. Primitive gut tube could be simply divided into foregut, midgut, and hindgut according to the anterior-posterior position. Later, foregut experienced a complicated fate determination process and formed the whole respiratory organ systems and the upper digestive system. In particular, the generation of the stomach, pancreas, liver, and intestine derived from a common pool of progenitors in the foregut endoderm, requiring the precise combinations of different signal pathways. BMP was not only required for hepatic specification from definitive endoderm both in human and mouse [13, 14] but also contributed to the posterization of gut tube patterning by upregulating the hindgut marker CDX2 and repressing the anterior gut marker SOX2 [25]. RA had been widely used to induce posterior foregut and pancreatic lineage [4–7, 9]. It had been reported RA treatment resulted in the expression of hepatic marker AFP when added directly to the Activin A-induced human ESCs [5, 12]. Therefore, the combination of RA and BMP inhibitor was expected to promote pancreatic lineage specification, which had been evidenced by multiple groups [4, 5, 8]. Our present data also demonstrated inhibition of BMP by various different chemicals greatly repressed hepatic lineage and facilitated pancreatic lineage differentiation in general (Figure 1, S1).

Furthermore, our results revealed that BMP inhibition reduced WNT activity during human endodermal patterning (Figure 2, S3). Consistent with our observation, there were several studies indicating the crosstalk between the BMP and WNT signal pathways in different animal models or developmental contexts. During caudal vein formation in zebrafish, BMP induced the expression of AGGF1, a beta-catenin transcriptional cofactor which activated beta-catenin and WNT activity [26]. Roarty and Serra demonstrated that TGFbeta regulated the expression of wingless-related protein family Wnt5a in tumor progression and metastasis [27].
Figure 5: Dual inhibition of BMP and WNT facilitated beta cell differentiation. (a, b) Generation of high INSULIN (red color) and nucleus transcription factor PDX1, NKX6-1 (green color) copositive population showed in "Dual i" and BMPi. (c) PDX1 (green color) and de novo INSULIN production markers Pro-INSULIN (red color) were evaluated by immunofluorescence in beta cell stage. (d) mRNA expression of PDX1, NKX6-1, and INSULIN between BMPi and "Dual i" exhibited in beta cell stage. * represented for p value < 0.05 and ** for p value < 0.01 by Student’s t-test (n = 3).
Figure 6: Dual inhibition of BMP and WNT promoted pancreatic differentiation of human iPSCs. (a) Immunofluorescence showed the PDX1 and CDX2 expressions upon treated with BMP inhibitor (LDN193189) compared to the control group. Scale bars for enlargement inset, 50 μm. (b) Protein levels of active beta-catenin and total beta-catenin were analyzed with control and BMPi by Western blotting (n = 3). GAPDH served as a loading control. (c) qPCR analysis showed the expression levels of WNT downstream genes including WNT3, TWIST1, AXIN2, and MYC between control and BMPi (n = 3). (d) Flow cytometric analysis displayed PDX1 between the BMPi and "Dual i" in PGP1 pancreatic differentiation (n = 3). (e) Immunofluorescence showed the progenitor markers PDX1 and NKX6-1 coexpression between the BMPi and "Dual i" groups at PP stage. (f) mRNA expression level of PDX1 and INSULIN between the BMPi and "Dual i" groups was revealed in beta cell stage. ** represented for p value < 0.01 and *** for p value < 0.001 by Student’s t-test (n = 3). (g) Immunofluorescence showed the beta cell markers PDX1 and INSULIN coexpression at beta cell stage between the BMPi and "Dual i" groups.
Figure 7: Continued.
Placencio and colleagues showed TGFβ signaling mediated prostatic response by paracrine WNT activity [28]. In rat neuronal differentiation from hippocampal neural stem and progenitor cells, BMP2 and BMP4 induced neurogenesis in a WNT-dependent manner. Furthermore, BMP also cooperated with WNT signaling to specify neuronal fate specification [29]. In addition, BMP2 could induce the WNT and planar cell polarity pathways to contribute to vascular smooth muscle motility [30]. A combinational treatment with BMP inhibitors (Noggin and Gremlin) and WNT inhibitor Frzb could give rise to the cranial muscle anlagen and promote myogenesis [31]. In a recent report, activation of BMP signaling was found to be required and together with WNT signaling to direct differentiated gut tube into colonic organoids [32]. In addition, Wei and colleagues recently reported that TGFβ signaling desensitized basal cells from growth inhibitory effect of stromal WNT signaling in prostate epithelial progenitor [33]. Our results together suggested that BMP inhibitor promoted pancreatic differentiation possibly through two pathways: the well-known direct inhibitory effect for hepatic lineage and the indirect inhibitory effect for intestinal lineage mainly through inhibiting WNT signaling [21]. Our data indicated that BMP inhibition could decrease WNT activity and together promoted pancreatic differentiation, though how BMP inhibition resulted in decreased WNT activity during endodermal patterning remained to be dissected in future study.

Canonical WNT plays a key role in endoderm differentiation along with Nodal signal, whereas its upregulation is also required for gut lineage after endoderm [21]. Very recently, McCracken and colleagues reported that activated WNT signaling also promoted gastric fund differentiation in both rodents and human [34]. They observed that in E10.5 Shh-cre; beta-cateninfl/fl mouse embryos, beta-catenin was deleted in foregut-derived stomach budding region; the prestomach region was completely mispatterned with ectopic PDX1 expression [34]. This observation strongly suggested endogenous WNT signaling blocked pancreatic lineage specification. In addition, although WNT and BMP were generally considered to promote hindgut differentiation [21, 35], both of them played more complicated roles in the precise regulation of cell fate determination for different organ buds.

We had determined the effect of WNT inhibitor only, compared to BMP inhibitor only and dual inhibitors (Figure 3). WNT inhibition alone indeed showed improved effect in terms of promoting pancreatic lineage marker expression, which was consistent with a recent report [36]; however, dual inhibition exhibited much better expression levels of pancreatic markers and more PDX1- and INSULIN-positive cells (Figure S4).

Taken together, these data combined with our study point out that precise combination, rather than one single signal self, determined the organ patterning. Understanding the precise signal crosstalk between WNT and BMP has
greatly helped the directed pancreatic differentiation from human pluripotent stem cells.

5. Conclusion

We had identified that a combination of dual inhibition of the BMP and WNT signaling pathways could greatly promote pancreatic differentiation and beta cell generation from human pluripotent stem cells (i.e., human ESCs and iPSCs).

Data Availability

The data used to support the finding of this study are included within the article.

Conflicts of Interest

The authors declared no potential conflicts of interest.

Authors’ Contributions

Tan M performed the experiments, analyzed the data, and drafted the manuscript. Jiang L and Li Y performed the experiments and prepared parts of graphs and figures. Jiang W supervised this study, reviewed the data, and finalized the manuscript. All authors read and approved the final manuscript.

Acknowledgments

We would like to thank Ran Liu and other laboratory members for the technical help and discussion. Grants from the National Key Research and Development Program of China (No. 2016YFA0503100), the National Natural Science Foundation of China (No. 91740102, 31970608), and the Medical Science Advancement Program of Wuhan University (No. TFZZ2018053, TFJC2018002) are greatly appreciated.

Supplementary Materials

The supplementary material files includes four supplemental figures (Figure S1-S4, including figure legends) and two supplemental tables (Table S1-S2). Figure S1: the PDX1/AFP/CDX2 expression under various BMP inhibitor treatment. Figure S2: the endodermal lineage differentiation upon treated with BMP inhibitor K02288. Figure S3: BMP inhibitor K02288 regulated pancreatic differentiation via decreased WNT activity. Figure S4: the beta cell generation upon treated with WNT inhibitor. Table S1: information of chemical compounds used in this study. Table S2: information of antibodies used in this study. (Supplementary Materials)

References

[1] A. M. Shapiro, M. Pokrywcynska, and C. Ricordi, "Clinical pancreatic islet transplantation," Nature Reviews Endocrinology, vol. 13, no. 5, pp. 268–277, 2017.

[2] J. A. Thomson, J. Itskovitz-Eldor, S. S. Shapiro et al., "Embryonic stem cell lines derived from human blastocysts," Science, vol. 282, no. 5391, pp. 1145–1147, 1998.

[3] K. Takahashi, K. Tanabe, M. Ohnuki et al., "Induction of pluripotent stem cells from adult human fibroblasts by defined factors," Cell, vol. 131, no. 5, pp. 861–872, 2007.

[4] E. Koon, L. A. Martinson, K. Kadoya et al., "Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo," Nature Biotechnology, vol. 26, no. 4, pp. 443–452, 2008.

[5] D. Zhang, W. Jiang, M. Liu et al., "Highly efficient differentiation of human ES cells and iPSCs into mature pancreatic insulin-producing cells," Cell Research, vol. 19, no. 4, pp. 429–438, 2009.

[6] A. Rezania, J. E. Bruin, P. Arora et al., "Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells," Nature Biotechnology, vol. 32, no. 11, pp. 1121–1133, 2014.

[7] F. W. Pagliuca, J. R. Millman, M. Gurtler et al., "Generation of functional human pancreatic β cells in vitro," Cell, vol. 159, no. 2, pp. 428–439, 2014.

[8] M. C. Nostro, F. Sarangi, C. Yang et al., "Efficient generation of NKK6-1′ pancreatic progenitors from multiple human pluripotent stem cell lines," Stem Cell Reports, vol. 4, no. 4, pp. 591–604, 2015.

[9] W. Jiang, Y. Shi, D. Zhao et al., "In vitro derivation of functional insulin-producing cells from human embryonic stem cells," Cell Research, vol. 17, no. 4, pp. 333–344, 2007.

[10] R. I. Sherwood, T. Y. Chen, and D. A. Melton, "Transcriptional dynamics of endodermal organ formation," Developmental Dynamics, vol. 238, no. 1, pp. 29–42, 2009.

[11] A. M. Zorn and J. M. Wells, "Vertebrate endoderm development and organ formation," Annual Review of Cell and Developmental Biology, vol. 25, pp. 221–251, 2009.

[12] C. Davenport, U. Diekmann, I. Budde, N. Detering, and O. Naujok, "Anterior-posterior patterning of definitive endoderm generated from human embryonic stem cells depends on the differential signaling of retinoic acid, Wnt-, and BMP-signaling," Stem Cells, vol. 34, no. 11, pp. 2635–2647, 2016.

[13] J. Cai, Y. Zhao, Y. Liu et al., "Directed differentiation of human embryonic stem cells into functional hepatic cells," Hepatology, vol. 45, no. 5, pp. 1229–1239, 2007.

[14] V. Gouon-Evans, L. Boussermart, P. Gadue et al., "BMP-4 is required for hepatic specification of mouse embryonic stem cell-derived definitive endoderm," Nature Biotechnology, vol. 24, no. 11, pp. 1402–1411, 2006.

[15] T. C. Schulz, H. Y. Young, A. D. Agulnick et al., "A scalable system for production of functional pancreatic progenitors from human embryonic stem cells," PLoS One, vol. 7, no. 5, article e37004, 2012.

[16] W. Jiang, X. Sui, D. Zhang et al., "CD24: a novel surface marker for PDX1-positive pancreatic progenitors derived from human embryonic stem cells," Stem Cells, vol. 29, no. 4, pp. 609–617, 2011.

[17] W. Jiang, Y. Liu, R. Liu, K. Zhang, and Y. Zhang, "The IncRNA DEANR1 Facilitates Human Endoderm Differentiation by Activating FOXA2 Expression," Cell Reports, vol. 11, no. 1, pp. 137–148, 2015.

[18] G. Wang, M. L. McCain, L. Yang et al., "Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies," Nature Medicine, vol. 20, no. 6, pp. 616–623, 2014.
[19] R. E. Jennings, A. A. Berry, J. P. Strutt, D. T. Gerrard, and N. A. Hanley, "Human pancreas development," *Development*, vol. 142, no. 18, pp. 3126–3137, 2015.

[20] H. P. Shih, A. Wang, and M. Sander, "Pancreas organogenesis: from lineage determination to morphogenesis," *Annual Review of Cell and Developmental Biology*, vol. 29, pp. 81–105, 2013.

[21] J. R. Spence, C. N. Mayhew, S. A. Rankin et al., "Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro," *Nature*, vol. 470, no. 7332, pp. 105–109, 2011.

[22] B. T. MacDonald, K. Tamai, and X. He, "Wnt/β-catenin signaling: components, mechanisms, and diseases," *Developmental Cell*, vol. 17, no. 1, pp. 9–26, 2009.

[23] D. Kimelman and W. Xu, "β-Catenin destruction complex: insights and questions from a structural perspective," *Onco-gene*, vol. 25, no. 57, pp. 7482–7491, 2006.

[24] J. Rhee, N. S. Mahfouz, C. Arregui, J. Lilien, J. Balsamo, and M. F. VanBerkum, "Activation of the repulsive receptor roundabout inhibits N-cadherin-mediated cell adhesion," *Nature Cell Biology*, vol. 4, no. 10, pp. 798–805, 2002.

[25] K. M. Loh, L. T. Ang, J. Zhang et al., "Efficient endoderm induction from human pluripotent stem cells by logically directing signals controlling lineage bifurcations," *Cell Stem Cell*, vol. 14, no. 2, pp. 497–509, 2015.

[26] T. Kashiwada, S. Fukuhara, K. Terai et al., "β-Catenin-dependent transcription is central to Bmp-mediated formation of venous vessels," *Development*, vol. 142, no. 3, pp. 497–509, 2015.

[27] K. Roarty and R. Serra, "Wnt5a is required for proper mammary gland development and TGF-beta-mediated inhibition of ductal growth," *Development*, vol. 134, no. 21, pp. 3929–3939, 2007.

[28] V. R. Placencio, A. R. Sharif-Afshar, X. Li et al., "Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity," *Cancer Research*, vol. 68, no. 12, pp. 4709–4718, 2008.

[29] T. Armenteros, Z. Andreu, R. Hortiguela, D. C. Lie, and H. Mira, "BMP and WNT signalling cooperate through LEF1 in the neuronal specification of adult hippocampal neural stem and progenitor cells," *Scientific Reports*, vol. 8, no. 1, p. 9241, 2018.

[30] V. A. Perez, Z. Ali, T. P. Alastalo et al., "BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways," *The Journal of Cell Biology*, vol. 192, no. 1, pp. 171–188, 2011.

[31] E. Tzahor, H. Kempf, R. C. Mootooosamy et al., "Antagonists of Wnt and BMP signaling promote the formation of vertebrate head muscle," *Genes & Development*, vol. 17, no. 24, pp. 3087–3099, 2003.

[32] J. O. Múnera, N. Sundaram, S. A. Rankin et al., "Differentiation of human pluripotent stem cells into colonic organoids via transient activation of BMP signaling," *Cell Stem Cell*, vol. 21, no. 1, pp. 51–64.e6, 2017.

[33] X. Wei, L. Zhang, Z. Zhou et al., "Spatially restricted stromal Wnt signaling restrains prostate epithelial progenitor growth through direct and indirect mechanisms," *Cell Stem Cell*, vol. 24, no. 5, pp. 753–768.e6, 2019.

[34] K. W. McCracken, E. Aihara, B. Martin et al., "Wnt/β-catenin promotes gastric fundus specification in mice and humans," *Nature*, vol. 541, no. 7636, pp. 182–187, 2017.

[35] X. Zhang, Y. Chen, Y. Ye et al., "Wnt signaling promotes hindgut fate commitment through regulating multi-lineage genes during hESC differentiation," *Cellular Signalling*, vol. 29, pp. 12–22, 2017.

[36] N. Sharon, J. Vanderhoof, J. Straubhaar et al., "Wnt signaling separates the progenitor and endocrine compartments during pancreas development," *Cell Reports*, vol. 27, no. 8, pp. 2281–2291.e5, 2019, e2285.